Best practice in precision medicine for prostate cancer

ESMO 2025: Latest in EGFR mutant NSCLC

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Non-clear cell renal cell carcinoma: Management of papillary RCC

WCLC 2025: Latest in EGFR positive NSCLC

Latest advances in chronic lymphocytic leukaemia

ASCO 2025: Highlights and analysis

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers